With the acquisition, Qiagen will integrate N-of-One’s MarkerMine database into its core technology to help customers design new, targeted therapies.
The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.
The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.
The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.
With the acquisition, Luminex has expanded its offering of flow-based detection systems and broadened direct interactions with researchers conducting cellular analysis.
The company, which had raised $55.5 million in February, said its investors have agreed to contribute an additional $30 million.
There were more mergers and acquisitions in the omics space in 2018, reversing the decline experienced in 2017.
The company will continue to explore strategic alternatives with financial advisor Raymond James & Associates.
The transaction follows 10x Genomics' acquisition of Stanford University spinout Epinomics and technology development partnerships with BioLegend and Immudex.
PacBio's shares skyrocketed 76 percent in November on the news that Illumina plans to acquire the firm for $1.2 billion in cash.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.